GraphWear, the company pioneering needle-free disease monitoring, today announced an executive hire and a new board member. Dana Cambra and Woody Scal will serve as key players in driving the company's mission forward as GraphWear develops its non-invasive disease management platform.
Dana Cambra, Senior Vice President of Engineering, brings over 30 years of experience researching, developing and revolutionizing world-class health technology. At GraphWear, Cambra will lead the company toward the commercialization of its novel product.
As a Dexcom Inc. (NYSE: DXCM) veteran, Cambra brings expertise in diabetes health management. He led the development of the Dexcom G6 continuous glucose monitor (CGM), the first non-adjunctive non-calibration glucose monitoring platform that brought the industry of health management forward exponentially. With decades devoted to transforming medicine to enhance patient care, Cambra will apply his years of industry knowledge to GraphWear's non-invasive approach, working on expanding and further modernizing healthcare solutions for millions.
“GraphWear has a holy grail opportunity to transform areas of healthcare the industry hasn't explored for decades,” said Dana Cambra, Senior Vice President of Engineering at GraphWear. “With experience in CGM technology, I immediately recognized and was drawn to GraphWear's disruptive influence on not only diabetes but overall health management.”
Woody Scal joins GraphWear as an independent member of the company's board of directors, bringing over 25 years of experience leading high-growth consumer-driven health and fitness companies. He currently serves as Executive Chair of Fresh Health, an oral care company, and is on the board of Tonal and DOTS. Scal has also been a board member or advisor to Owlet, Pendulum Therapeutics and TytoCare.
Scal previously served as the Chief Business Officer of Fitbit, overseeing the company's rapid business growth and global expansion while managing all marketing, sales, and new business development activities, across the company's consumer, corporate wellness and digital health divisions. During his tenure, Fitbit's revenue grew from $5M to over $2.1B and the company expanded into over 63 countries. His wealth of leadership experience also includes executive positions at CamelBak, General Mills and Visa International.
“I firmly believe that GraphWear will crack the code on non-invasive CGM with a more convenient, comfortable, and cost-effective solution, and this can have a profound impact on the way the world manages chronic illnesses,” said Woody Scal, member of GraphWear's Board of Directors. “I'm excited about GraphWear's growth and potential to open up glucose monitoring to existing and new applications, creating a range of opportunities for the company to empower individuals to improve their health.”
“With our recent Series B funding under our belts and clinical trials in the pipeline, we knew onboarding these leaders would only propel the company forward on the right trajectory,” said Rajatesh Gudibande, co-founder and CEO of GraphWear. “Our goal to transform healthcare starts from the inside. With Dana's impressive background assisting our technical advancements, I'm excited to see where his expertise can take the company. Woody's vast experience leading health and fitness companies, paired with his passion for impactful innovations, make him the perfect addition to GraphWear's board. I'm honored to work with both of them as we look to reinvent and transform the way we monitor human health and map human physiology.”
This announcement comes on the heels of GraphWear's Series B funding, positioning the company to further advance its research and support the clinical trials of its first-of-its-kind, no-blood, no-needle approach to disease monitoring.
To learn more about how GraphWear is empowering broad access to health monitoring and to view open positions within the company, please visit https://www.graphwear.co.
About GraphWear
GraphWear is reinventing the way we map human health. Pioneering a no-needle, no-blood approach to disease monitoring, GraphWear's technology offers the first genuinely non-invasive method to map patient health, unlocking a new adherence for some of the most significant chronic diseases. By empowering access to accurate and timely health information in an easy-to-use format, GraphWear aims to drive greater efficiency across diagnosis, management, and care. GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer. The company has raised a combined $25 million from investors like Mayfield, MissionBio Capital, Builders VC and VSC Ventures. ​​For more information, visit: www.graphwear.co.
— WebWireID285400 —
